Other Viruses Citation List: December 7 - December 20, 2012

Epstein-Barr Virus

1. Resveratrol Prevents EBV Transformation and Inhibits the Outgrowth of EBV-immortalized Human B Cells. Espinoza, J.L., A. Takami, L.Q. Trung, S. Kato, and S. Nakao. PloS One, 2012. 7(12): p. e51306; PMID[23251493].

[PubMed] OV_1207-122012.

2. Synthesis and Docking Studies of Novel Antitumor Benzimidazoles. Omar, M.A., Y.M. Shaker, S.A. Galal, M.M. Ali, S.M. Kerwin, J. Li, H. Tokuda, R.A. Ramadan, and H.I. El Diwani. Bioorganic & Medicinal Chemistry, 2012. 20(24): p. 6989-7001; PMID[23123017].

[PubMed] OV_1207-122012.

Hepatitis B Virus

3. New Amide Alkaloids from Piper longum. Jiang, Z.Y., W.F. Liu, C.G. Huang, and X.Z. Huang. Fitoterapia, 2012. [Epub ahead of print]; PMID[23232323].

[PubMed] OV_1207-122012.

4. Development and in Vivo/in Vitro Evaluation of Novel Herpetrione Nanosuspension. Guo, J.J., P.F. Yue, J.L. Lv, J. Han, S.S. Fu, S.X. Jin, S.Y. Jin, and H.L. Yuan. International Journal of Pharmaceutics, 2012. [Epub ahead of print]; PMID[23220096].

[PubMed] OV_1207-122012.

5. Dioscin's Antiviral Effect in Vitro. Liu, C., Y. Wang, C. Wu, R. Pei, J. Song, S. Chen, and X. Chen. Virus Research, 2012. [Epub ahead of print]; PMID[23238077].

[PubMed] OV_1207-122012.

Hepatitis C Virus

6. Discovery and Characterization of a Novel 7-Aminopyrazolo[1,5-a]pyrimidine Analog as a Potent Hepatitis C Virus Inhibitor. Hwang, J.Y., M.P. Windisch, S. Jo, K. Kim, S. Kong, H.C. Kim, S. Kim, H. Kim, M.E. Lee, Y. Kim, J. Choi, D.S. Park, E. Park, J. Kwon, J. Nam, S. Ahn, J. Cechetto, J. Kim, M. Liuzzi, Z. No, and J. Lee. Bioorganic & Medicinal Chemistry Letters, 2012. 22(24): p. 7297-7301; PMID[23159569].

[PubMed] OV_1207-122012.

7. Boceprevir: A Recently Approved Protease Inhibitor for Hepatitis C Virus Infection. Lam, J.T. and S. Jacob. American Journal of Health-System Pharmacy, 2012. 69(24): p. 2135-2139; PMID[23230035].

[PubMed] OV_1207-122012.

8. Synthesis and Antiviral Activity of Novel HCV NS3 Protease Inhibitors with P4 Capping Groups. Li, X., Y. Liu, Y.K. Zhang, J.J. Plattner, S.J. Baker, W. Bu, L. Liu, Y. Zhou, C.Z. Ding, S. Zhang, W.M. Kazmierski, R. Hamatake, M. Duan, L.L. Wright, G.K. Smith, R.L. Jarvest, J.J. Ji, J.P. Cooper, M.D. Tallant, R.M. Crosby, K. Creech, and A. Wang. Bioorganic & Medicinal Chemistry Letters, 2012. 22(24): p. 7351-7356; PMID[23142614].

[PubMed] OV_1207-122012.

9. Structure Based Medicinal Chemistry Approach to Develop 4-Methyl-7-deazaadenine carbocyclic nucleosides as anti-HCV Agent. Thiyagarajan, A., M.T. Salim, T. Balaraju, C. Bal, M. Baba, and A. Sharon. Bioorganic & medicinal chemistry letters, 2012. 22(24): p. 7742-7747; PMID[23122860].

[PubMed] OV_1207-122012.

HSV-1

10. 2-Arachidonoyl-glycerol- and Arachidonic acid-stimulated Neutrophils Release Antimicrobial Effectors against E. coli, S. aureus, HSV-1, and RSV. Chouinard, F., C. Turcotte, X. Guan, M.C. Larose, S. Poirier, L. Bouchard, V. Provost, L. Flamand, N. Grandvaux, and N. Flamand. Journal of Leukocyte

Biology, 2012. [Epub ahead of print]; PMID[23242611].

[PubMed] OV_1207-122012.

11. Synthesis of C3-arylated-3-deazauridine Derivatives with Potent anti-HSV-1 Activities. Lalut, J., L. Tripoteau, C. Marty, H. Bares, N. Bourgougnon, and F.X. Felpin. Bioorganic & Medicinal Chemistry Letters, 2012. 22(24): p. 7461-7464; PMID[23141915].

[PubMed] OV_1207-122012.

Citations from the ISI Web of Knowledge Listings for O.V.

12. Preclinical Studies of PF-04849285, an Interferon-alpha 8 Fusion Protein for the Treatment of HCV. Flores, M.V., T.P. Hickling, S. Sreckovic, M.D. Fidock, N. Horscroft, M. Katragadda, B. Savic, J. Rawal, O.E. Delpuech-Adams, N. Robas, T. Corey, L. Nelms, M. Lawton, J. Marcek, M. Stubbs, M. Westby, and G. Ciaramella. Antiviral Therapy, 2012. 17(5): p. 869-881; ISI[000311080200012]

[WOS] OV_1207-122012.

13. Treatment with Silymarin for Hepatitis C Virus Reply. Fried, M.W., R.L. Hawke, and K.R. Reddy. JAMA-Journal of the American Medical Association, 2012. 308(18): p. 1857-1857; ISI[000310952700012].

[WOS] OV_1207-122012.

14. Iron Regulator Hepcidin Exhibits Antiviral Activity against Hepatitis C Virus. Liu, H.Y., T. Le Trinh, H.J. Dong, R. Keith, D. Nelson, and C. Liu. PloS One, 2012. 7(10): p. e46631; ISI[000310193400005].

[WOS] OV_1207-122012.

15. Anti-retroviral Drugs Do Not Facilitate Hepatitis C Virus (HCV) Infection in Vitro. Sandmann, L., M. Wilson, D. Back, H. Wedemeyer, M.P. Manns, E. Steinmann, T. Pietschmann, T. von Hahn, and S. Ciesek. Antiviral Research, 2012. 96(1): p. 51-58; ISI[000310668000006].

[WOS] OV_1207-122012.

16. Anti-Hepatitis C Virus E2 (HCV/E2) Glycoprotein Monoclonal Antibodies and Neutralization Interference. Sautto, G., N. Mancini, R.A. Diotti, L. Solforosi, M. Clementi, and R. Burioni. Antiviral Research, 2012. 96(1): p. 82-89; ISI[000310668000010].

[WOS] OV_1207-122012.

17. Direct-acting Antiviral Agents for the Treatment of HCV. Thompson, A.J. and S. Locarnini. Antiviral Therapy, 2012. 17(6): p. 1105-1107; ISI[0003112406000].

[WOS] OV_1207-122012.